Head-to-head comparison
| Property | Teriparatide | Abaloparatide |
|---|---|---|
| Category | Other | Other |
| Legal Status | Prescription | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~1 hour | ~1.7 hours |
| Mol. Weight | 4,117.8 Da | 3,961 Da |
| Side Effects | Nausea, Dizziness (orthostatic hypotension), Leg cramps | Hypercalciuria, Dizziness (orthostatic hypotension), Nausea |
Key differences
- Molecular source: Teriparatide is recombinant human PTH(1-34), identical to the N-terminal fragment of endogenous parathyroid hormone; abaloparatide is a synthetic 34-amino-acid analog of parathyroid hormone-related peptide (PTHrP) with targeted substitutions.
- Receptor signaling bias: Both activate PTH1R on osteoblasts, but abaloparatide favors the transient RG receptor conformation, which preferentially stimulates bone formation while producing a less pronounced increase in bone resorption markers than teriparatide.
- Pivotal head-to-head data: The VERO trial directly compared abaloparatide to teriparatide in postmenopausal women with severe osteoporosis and reported comparable protection against vertebral fractures, with abaloparatide showing a faster onset of effect on nonvertebral fracture risk reduction in the published analysis.
- Dosing: Teriparatide is 20 mcg subcutaneously once daily via multi-use pen; abaloparatide is 80 mcg subcutaneously once daily via its own dedicated pen device. Both are thigh or abdomen injections.
- Boxed warning: Both carry an identical osteosarcoma warning based on dose- and duration-dependent tumor findings in rat studies; postmarketing human surveillance has not established a clear increase in osteosarcoma incidence.
- Lifetime use cap: Both are capped at a cumulative 24 months of use across a patient's lifetime, a restriction tied directly to the rat osteosarcoma signal rather than to observed human harm.
- Follow-on therapy: Neither agent is intended as monotherapy long-term. Both should be followed by an antiresorptive (bisphosphonate or denosumab) to consolidate the BMD gains, or bone density losses begin within months of discontinuation.
The verdict
Teriparatide and abaloparatide occupy the same clinical niche: short-course bone-anabolic therapy for patients at very high fracture risk, followed by antiresorptive consolidation. VERO data support broadly equivalent vertebral fracture protection, with abaloparatide showing an earlier nonvertebral fracture signal and a slightly less pronounced resorption marker rise. In practice, the choice is often driven by formulary access, device preference, and clinician experience rather than by a decisive efficacy gap. The shared osteosarcoma warning and 24-month cap apply equally, so neither offers a longer treatment window. For most very-high-risk patients, either is a defensible first choice when bisphosphonates alone are inadequate.
Frequently asked questions
The VERO head-to-head trial in postmenopausal women with severe osteoporosis reported comparable vertebral fracture protection between the two agents, with abaloparatide showing a faster onset of nonvertebral fracture risk reduction in the published analysis. Long-term extension data remain limited. For most clinical decisions, efficacy is treated as broadly equivalent.
The cap originates from rat carcinogenicity studies where prolonged high-dose PTH-receptor stimulation produced dose- and duration-dependent osteosarcoma. Regulators applied a conservative lifetime ceiling of 24 cumulative months in humans. Postmarketing surveillance has not established a clear osteosarcoma signal in humans, but the cap remains in place across both labels.
The 24-month lifetime cap is cumulative across PTH-receptor anabolics, so the two cannot be sequenced back-to-back beyond the combined limit. Patients who complete a full course of one typically transition directly to antiresorptive therapy. Sequential use within the cumulative window is not a standard strategy and is not supported by controlled data.
Pivotal rat carcinogenicity studies showed a strong, dose-dependent osteosarcoma signal with long-duration PTH-receptor stimulation. Human postmarketing registries tracking teriparatide for over a decade have not established a comparable signal, but regulators retained the boxed warning as a precautionary measure because the mechanism-of-action concern cannot be ruled out without very long follow-up.
Guidelines increasingly favor anabolic-first sequencing — teriparatide or abaloparatide up front in very-high-risk patients, followed by a bisphosphonate or denosumab — because anabolic gains are partially blunted when used after long bisphosphonate exposure. In practice, many patients still arrive on bisphosphonates first. Either sequence is defensible; anabolic-first tends to produce larger BMD gains.
Yes. Follow-on teriparatide products have been approved in the US and other markets and are generally priced below the originator. These are typically handled as biosimilars or generic follow-ons depending on jurisdiction. Abaloparatide remains single-source at time of writing, which contributes to its higher listed cost relative to follow-on teriparatide.